Rhumbline Advisers Has $1 Million Stake in Evolus, Inc. (NASDAQ:EOLS)

Rhumbline Advisers lifted its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 4.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 83,436 shares of the company’s stock after purchasing an additional 3,287 shares during the period. Rhumbline Advisers owned approximately 0.13% of Evolus worth $1,004,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. boosted its holdings in Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock valued at $368,000 after acquiring an additional 2,989 shares during the last quarter. Barclays PLC grew its holdings in Evolus by 12.9% during the 4th quarter. Barclays PLC now owns 105,786 shares of the company’s stock worth $1,167,000 after acquiring an additional 12,124 shares during the period. Frontier Capital Management Co. LLC bought a new position in shares of Evolus in the 4th quarter worth $2,648,000. Raymond James Financial Inc. bought a new stake in shares of Evolus in the 4th quarter valued at about $575,000. Finally, Comerica Bank acquired a new position in Evolus during the fourth quarter valued at approximately $312,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Finally, Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus has a consensus rating of “Buy” and a consensus price target of $23.75.

Evolus Price Performance

Shares of EOLS opened at $9.30 on Friday. The company has a market cap of $599.66 million, a price-to-earnings ratio of -10.45 and a beta of 1.00. The company has a current ratio of 2.34, a quick ratio of 2.16 and a debt-to-equity ratio of 22.00. The company’s fifty day simple moving average is $10.27 and its 200 day simple moving average is $11.68. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82.

Insider Transactions at Evolus

In other news, insider Rui Avelar sold 3,385 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the transaction, the insider now owns 359,082 shares of the company’s stock, valued at approximately $3,544,139.34. This represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares of the company’s stock, valued at $6,306,875.60. This trade represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 159,822 shares of company stock worth $1,614,602 in the last ninety days. Insiders own 5.90% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.